Nucleus plus
  • Patient Care
  • About
 
 

12.21.22

CRISPR-Cas9 Gene Editing Used to Refine Allogeneic CAR T Cells

by Eleanor Mayfield, ELS

Two studies published in October report noteworthy advances in the use of CRISPR-Cas9 gene editing technology to refine allogeneic CAR T-cell therapy. One study describes what the researchers say is, to their knowledge, the first use of Sleeping Beauty (SB) transposons with CRISPR-Cas9 to efficiently produce allogeneic TCR-disrupted CD-19 CAR T cells. The other reports the results of a first-in-human clinical trial of CRISPR-engineered allogeneic CD19 CAR T cells in six children with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.

A research team in Belgium described optimizing and validating a non-viral system based on SB transposon–mediated expression of CD19-targeted CARs and targeted inactivation of endogenous TCR genes using CRISPR-Cas9 ribonucleoparticles to engineer off-the-shelf human CAR T cells free of endogenous TCR.

“The resulting CAR T cells are highly functional against CD19-expressing target cells and CD19+ tumor-bearing mice for tumor eradication with reduced TCR alloreactivity and GvHD development,” write senior authors Marinee K. CHuah and Thierry VandenDriessche of the Free University in Brussels and colleagues in a paper published in Molecular Therapy.

Researchers at the Great Ormond Street Hospital for Children NHS Trust in London, UK, describe employing CRISPR-Cas9 editing and linked CAR expression to devise an investigational T-cell therapy that they then tested in a single-center phase I trial. The work built on a previous approach in which T cells modified with transcription-activator-like effector nucleases were used to disrupt endogenous TCR alpha chain and CD52 genes in HLA-mismatched allogeneic CAR19 T cells.

Four of the six patients infused with the investigational T cells “exhibited cell expansion, achieved flow cytometric remission, and then proceeded to receive allogeneic stem cell transplantation.” The phase I study “provides encouraging early-stage evidence of [the] feasibility, safety, and therapeutic potential [of] CRISPR-Cas9 editing,” write senior author Waseem Qasim and colleagues In a paper published in Science Translational Medicine.

  • Ottaviano G, Georgiadis C, Gkazi SA, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14(668):eabq3010. doi:10.1126/scitranslmed.abq3010
  • Tipanee J, Samara-Kuko E, Gevaert T, Chuah MK, VandenDriessche T. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol Ther. 2022;30(10):3155-3175. doi:10.1016/j.ymthe.2022.06.006
Inflammatory Cytokine Levels “Increased in Atrial Fibrillation After CAR T Therapy
01.05.23
Inflammatory Cytokine Levels “Increased in Atrial Fibrillation After CAR T Therapy
by Eleanor Mayfield, ELS
Adoptive immunotherapy for AML using CAR.CD123-NK cells
12.22.22
Adoptive immunotherapy for AML using CAR.CD123-NK cells
by ASTCT Science Highlights
CRISPR-Cas9 Gene Editing Used to Refine Allogeneic CAR T Cells
12.21.22
CRISPR-Cas9 Gene Editing Used to Refine Allogeneic CAR T Cells
by Eleanor Mayfield, ELS
footer divider

ASTCT

American Society for Transplantation
and Cellular Therapy

330 North Wabash Avenue, Suite 2000
Chicago, IL 60611, USA
Phone: (312) 321-6820
Fax: (312) 673-6733

facebook youtube twitter linkedin
Login
Search